drugset / Trial / NCT00277810

Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease

NCT00277810

Phase 2/3 Completed 250 enrolled Pfizer
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of the study is to determine the safety, tolerability, and efficacy of 3 doses of lecozotan in combination with a cholinesterase inhibitor in patients with mild to moderate Alzheimer's disease (AD).

Timeline

Start
2006-03
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Lecozotan Small molecule 2 mg
Subject Lecozotan Small molecule 5 mg
Subject Lecozotan Small molecule 10 mg

Indications